PrEP Assistance Program Act
Summary
HR7385 is an early-stage bill authorizing up to $10M per grant for PrEP programs, with no specified total funding or direct corporate beneficiaries. It has been referred to committee with 14 cosponsors, all Democrats. At this procedural stage, the bill has no measurable market impact.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR7385 is an early-stage authorization bill with zero appropriated funding
- 2.All 14 cosponsors are Democrats—low passage probability in Republican-controlled House
- 3.No direct corporate beneficiaries; the funding mechanism is grants to eligible entities, not contracts to drug manufacturers
Market Implications
No market implications at this stage. The bill is purely procedural. If it advanced to a committee markup with a specified funding amount ($500M+), Gilead Sciences ($GILD) would be the primary beneficiary as the dominant PrEP manufacturer. But that scenario requires the bill to pass a Republican House and be signed into law—a low-probability event. No action required for retail investors.
Full Analysis
HR7385, the PrEP Assistance Program Act, was introduced on February 4, 2026, and referred to the House Committee on Energy and Commerce. The bill authorizes the CDC and HRSA to establish a grant program for pre-exposure prophylaxis (PrEP) for HIV prevention, with grants capped at $10 million per eligible entity. No total appropriation is specified; this is an authorization-only bill. Actual funding would require a separate appropriations bill.
The bill has 14 cosponsors, all Democrats, and no Republican cosponsors. The sponsor, Rep. Watson Coleman (D-NJ), is a junior member without committee leadership. The bill is in the earliest legislative stage—no hearings, no markup, no CBO score. Passage probability in the Republican-controlled House is extremely low.
No executive actions are relevant to this bill. The DPA memoranda on energy infrastructure (Apr 20, 2026) have no connection to HIV prevention grant programs.
There are no publicly traded companies that derive material revenue from PrEP grant programs. PrEP drugs (Truvada, Descovy, Apretude) are manufactured by Gilead Sciences ($GILD) and ViiV Healthcare (GSK, $GSK), but this grant program does not mandate purchasing, name drug manufacturers, or allocate specific funding. The mechanism is grants to community organizations and health departments—not direct contracts to pharmaceutical companies. The $10M per-grant cap is too small to move stock prices for any public company.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
PrEP and PEP are Prevention Act
EPIC Act of 2025
End the Vaccine Carveout Act
Maternal Vaccination Act
Elijah E. Cummings Family Asthma Act
Protecting Americans from Unsafe Drugs Act of 2026
DELL FEDERAL SYSTEMS L.P: $1.0B Department of Veterans Affairs Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →